Veteran investor Marc Viscogliosi believes digital health, enhanced navigation, artificial intelligence, enhanced surgical planning capabilities, and customized 3D constructs will drive sustained change in the spine surgery industry, but have yet to prove their value in changing patient outcomes.
The merger of Globus Medical and NuVasive to form the second largest spine surgery company in the world has resonated throughout the spine industry and brought to the forefront a range of important trends related to future value creation. (See “The Pros and Cons of a Globus-NuVasive Merger,” MedTech Strategist, March 22, 2023.)
Marc Viscogliosi is one of the field’s most experienced CEOs, investors, and entrepreneurs, and a partner, along with his brothers Anthony and John, in Viscogliosi Brothers, a New York City merchant bank specializing in musculoskeletal companies. In the past 20 years, the firm has completed over $800 million in equity and debt capital raises at all levels of a company’s lifecycle, while generating over $2.2 billion in exit values for investor-partners and stakeholders.
With experiences in over a dozen issued medical device patents, several FDA PMA approvals, and leading products through the AMA’s CPT Coding and Payer Coverage Policy development processes, Viscogliosi has consistently shepherded start-ups into high-growth, high-performance organizations.He is the co-founder and was CEO of several companies, including Paradigm Spine (now part of SurgiAlign) and Knee Creations (acquired by Zimmer Biomet). Following news of the Globus-NuVasive deal, he shared his perspectives last month with MedTech Strategist on the inevitability of consolidation, given the industry’s maturity and fragmentation, and paths to increasing the value of innovation.